1. Introduction {#sec1}
===============

Bladder cancer is one of the most common malignancies of the urinary system and is the most common urinary system tumor in men \[[@B1]\]. At present, the main clinical treatment of bladder cancer is surgery combined with postoperative chemotherapy. However, bladder cancer is prone to drug resistance and recurrence, which makes the cure of bladder cancer more difficult. Early detection and timely intervention can significantly improve the survival rate of patients with bladder cancer. Timely monitoring the progress of drug-resistant bladder cancer is helpful for early targeted treatment of bladder cancer recurrence \[[@B2]\].

At present, the diagnosis and monitoring methods of bladder cancer are mainly urine cytology and cystoscopy. Cystoscopy is an invasive method for detection of bladder cancer, which is easy to cause anxiety and discomfort in patients \[[@B3]\]. Moreover, the sensitivity of cystoscopy to bladder cancer *in situ* (TIS) is low. Urine cytology is a noninvasive diagnostic method, which is less sensitive to small mastoid tumors, satellite lesions, and CIS both in the initial diagnosis and in the monitoring of recurrence. The sensitivity of cystoscopy is low, as low as 28%, and the median is 44% \[[@B4]\]. In addition, the cytological results are also affected by many factors, such as low production of exfoliated cells, urinary tract infection, and calculus, which will affect the clinical interpretation \[[@B5]\].

Urine biomarker detection can greatly improve the sensitivity and specificity of bladder cancer detection, which is a valuable choice. The ideal biomarker of bladder cancer is defined as an objective and noninvasive marker with high sensitivity and specificity \[[@B5]\], but in the existing urine tumor markers, the false-positive results are very common. During hematuria, inflammation, or infection, it is often unable to accurately judge the bladder tumor \[[@B3], [@B6]--[@B9]\].

Nucleophosmin 1 (NPM1) is a kind of protein that mainly locates in the nucleolus and shuttles between the nucleolus and the cytoplasm. Previous studies in our laboratory have shown that NPM1 can reflect specific biological behavior such as recurrence and drug resistance in bladder cancer. The expression of NPM1 in bladder cancer cells increases when the recurrence and drug resistance of invasive bladder cancer cells increase, suggesting that NPM1 may be an important prognostic indicator of bladder cancer cells \[[@B10]\]. However, as a protein only existing in cells, NPM1 has limited sensitivity as early monitoring of bladder cancer. Therefore, it is urgent to find a real-time and effective way to monitor the progress and recurrence of bladder cancer after treatment.

CD40, a transmembrane glycoprotein, is a member of the tumor necrosis factor receptor superfamily. The studies have shown that the CD40 molecule was found on the surface of antigen presenting cells (APC) \[[@B11]\], normal bladder cancer \[[@B12]\], gastric cancer \[[@B13]\], colon cancer \[[@B14]\], and other solid tumors and hematological tumor cells. CD40 molecules are differentially expressed in the process of tumorigenesis and tumor development. CD40 has been regarded as an important biomarker to predict the development in many cancers, such as ovarian cancer \[[@B5]\], hepatocellular carcinoma \[[@B6]\], and other tumors. Ghamade et al. demonstrated that recombinant CD40 ligand therapy had significant antitumor effect on CD40-positive ovarian tumors in mice, and antagonizing CD40 could enhance the effect of cisplatin \[[@B8]\], which means CD40 has a high diagnostic and therapeutic value \[[@B7]\].

CD40 has a variety of oncological activities in tumors, which provides an attractive choice for future clinical applications. As a cell surface secretory molecule, CD40 has a high sensitivity to reflect the biological changes of cells and can predict the biological behavior of tumor cells in the early stage. However, up to now, the differential expression and predictive value of CD40 have not been verified in drug-resistant bladder cancer.

Because NPM1 is closely related to drug-resistant bladder cancer, this study intends to explore the differential expression of CD40 in drug-resistant bladder cancer by mass spectrometry and analyze the correlation between NPM1 and CD40 in drug-resistant bladder cancer, so as to determine whether CD40 is a noninvasive biomarker that can predict the progress of bladder cancer.

2. Materials and Methods {#sec2}
========================

2.1. Subject and Groups {#sec2.1}
-----------------------

### 2.1.1. Drug-Resistant Cell Groups {#sec2.1.1}

The cisplatin-resistant bladder cancer cell lines (T24/0.8DDP, BIU87/0.3DDP, and PUMC-91/0.6DDP) were purchased from Beijing Shijitan Hospital Affiliated to Capital Medical University.

### 2.1.2. NPM1 Differential Expression Cell Groups {#sec2.1.2}

NPM1 silencing bladder cancer cell lines (T24/0.8DDP Lv-NPM1, BIU87/0.3DDP Lv-NPM1, and PUMC-91/0.6DDP Lv-NPM1): NPM1-silenced stable infection cell line was constructed by lentivirus infection containing NPM1 shRNA.

NPM1 silencing negative control groups (T24/0.8DDP Lv-NC, BIU87/0.3DDP Lv-NC, and PUMC-91/0.6DDP Lv-NC): the cell lines were constructed by lentivirus infection containing NPM1-negative shRNA.

2.2. Materials {#sec2.2}
--------------

0.25% of trypsin (17518012, Gibco Company, USA), RPMI 1640 (AE244464298, Hyclone Company, USA), fetal bovine serum (1861242, Gibco Company, USA), cisplatin (P4394, Sigma Company, USA), polyvinylidene fluoride (PVDF) membranes (ISEQ00010, Sigma Company, USA), mouse anti-nucleophosmin antibody (ab10530, Abcam Company, USA), rabbit anti-CD40 antibody (ab224639, Abcam Company, USA), goat anti-Mouse IgG H&L (HRP) (ab205719, Abcam Company, USA), and NPM1-silencing and NPM1 overexpressing and negative control lentivirus (GenePharma, China) were used.

2.3. Methods {#sec2.3}
------------

### 2.3.1. Lentivirus Infection and Establishment of Stable Cell Lines {#sec2.3.1}

T24/0.8DDP, PUMC-91/0.6DDP, and BIU-87/0.3DDP cells were infected with lentivirus containing NPM1 shRNA (NPM1 interference group) and negative control shRNA (NPM1 negative control group), respectively. The related protein validation and functional experiments were carried out 72 hours after infection. The stable infected cells were screened by single cell cloning. Clones were isolated and screened for stable culture. The isolated clones were amplified and cultured to establish stable cell lines.

### 2.3.2. Cell Culture {#sec2.3.2}

*(1) Drug Resistant Bladder Cancer Cell Groups*. T24/0.8DDP, BIU-87/0.3DDP, and PUMC-91/0.6DDP were cultured in the RPM I1640 medium containing 20% FBS and 0.8 *μ*g/ml DDP, 0.3 *μ*g/ml DDP, or 0.6 *μ*g/ml DDP and kept at 37°C in a 5% CO~2~ saturated humidity incubator, respectively. When cell growth fused into a single layer, the cells were digested and subcultured with 0.25% trypsin.

*(2) NPM1 Silencing Bladder Cancer Cell Groups*. T24/0.8DDP Lv-NPM1, BIU-87/0.3DDP Lv-NPM1, and PUMC-91/0.6DDP Lv-NPM1 were cultured in the RPM I1640 medium containing 20% FBS and kept at 37°C in a 5% CO~2~ saturated humidity incubator, respectively. When cell growth fused into a single layer, the cells were digested and subcultured with 0.25% trypsin.

*(3) The Corresponding Negative Control Cell Groups*. Human bladder cancer cell lines T24/0.8DDP Lv-NC, BIU-87/0.3DDP Lv-NC, and PUMC-91/0.6DDP Lv-NC were cultured in the RPMI 1640 medium containing 15% FBS and kept at 37°C in a 5% CO~2~ saturated humidity incubator, respectively. When cell growth fused into a single layer, the cells were digested and subcultured with 0.25% trypsin.

### 2.3.3. Western Blot {#sec2.3.3}

The total protein was extracted by a RIPA protein lysate. The protein was electrophoretized by SDS-PAGE at 120°V. Then, the protein was transferred to the nitrocellulose filter membranes. The nitrocellulose filter membranes were incubated overnight at 1 : 1,000 anti-NPM1 antibody, anti-CD40 antibody, and anti-*β*-actin antibody. The membranes were incubated at 4°C. The PBST buffer was used to rinse the membranes three times, each 20 minutes, 1 : 1,000 second antibody was added and incubated at room temperature for 90 minutes. The nitrocellulose filter membranes were rinsed by PBST and developed by the DAB kit. All experiments were repeated three times.

### 2.3.4. Mass Spectrometry {#sec2.3.4}

The cell samples were transferred to 1.5 ml microcentrifugal tubes. Then, the dissolving buffer (7 M urea, 2 M thiourea, and 0.1% CHAPS) was added to each sample, and the total protein was extracted by ultrasonic grinding. The supernatant was centrifuged for 30 minutes at 14,000 g for further experiments. Protein concentration was determined by the Bradford method. The appropriate amount of protein (100 *µ*l) was taken for electrophoresis. Gel dyeing and staining were performed until the results were clear. The experiment was repeated three times.

The peptides were separated by a Thermo Scientific EASY-nLC 1,000 system. The peptide mixtures were grouped according to the experimental requirements and labeled with TMT reagents. The mixture of peptides was dissolved in solution A (98% DDH and 2% acetonitrile, pH = 10). Then, the gradient solution B (2% DDH and 98% acetonitrile, pH = 10) was separated in a Durashell-C18 column (4.6 m × 250 m, 5 *µ*m, 100) at a flow rate of 0.7 ml/m. The separation gradient is shown in [Table 1](#tab1){ref-type="table"}. The isolated peptide was detected by a Q-Exactive mass spectrometer (Thermo Scientific). The spray voltage of the ion source was set to 2.1 kV. Full-scanning MS with a resolution of 70,000 was obtained in MS with a resolution of over 350--1,800 *m*/*z*. The spectral resolution of HCD was 17500 fhm. Standardized collision energy was set to 29%.

### 2.3.5. Proteomic Bioinformatics Analysis {#sec2.3.5}

Proteome Discoverer software was used to process the original mass spectrometry data. MS data were searched according to the human genome database and Uniprot website. The parameter settings for MaxQuant search are shown in [Table 2](#tab2){ref-type="table"}.

The biological processes, molecular functions, and cellular components of proteins were analyzed by gene ontology analysis (GO analysis). In addition, the Kyoto Encyclopedia of Genes and Genomes (KEGG) was used to study protein species in order to map the KEGG pathway for systematic functional biology interpretation (<http://www.genome.jp/kegg/>). Protein-protein interactions are obtained from a search tool that retrieves the Interacting Gene/Protein (String) database (<http://string-db.org/>), which contains known and predicted physical and functional protein-protein interactions.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All independent experimental data were expressed as mean ± standard deviation (SD). Statistical analysis was carried out by using Graphpad prism 6.0 statistical software Inc. (Lajolla, USA). *p* values were calculated by ANOVA and the Bonferroni test (more than two groups) or *t*-test (two groups). When *p* value\<0.05, the results are considered to be statistical.

3. Results {#sec3}
==========

3.1. Establishment of NPM1 Silencing Stable Cell Lines {#sec3.1}
------------------------------------------------------

We successfully established stable NPM1 silencing drug-resistant bladder cancer cell lines: the fluorescence efficiency of GFP in six kinds of cells (T24/0.8DDP Lv-NPM1, BIU-87/0.3DDP Lv-NPM1, PUMC-91/0.6DDP Lv-NPM1, and the corresponding negative controls) was observed by fluorescence microscopy, which reached more than 80%. Western blot was used to detect NPM1 expression. In the western blot analysis, the level of NPM1 protein in the T24/0.8DDP Lv-NPM1 cell line was 0.05-fold as high as that in T24/0.8DDP Lv-NC (*p* value\<0.05). The level of NPM1 protein in the BIU-87/0.3DDP Lv-NPM1 cell line was 0.35-fold as high as that in the corresponding negative control BIU-87/0.3DDP Lv-NC (*p* value\<0.05). The level of NPM1 protein in the PUMC-91/0.6DDP Lv-NPM1 cell line was 0.20-fold as high as that in the corresponding negative control PUMC-91/0.6DDP Lv-NC (*p* value\<0.05). The experimental results are shown in [Figure 1](#fig1){ref-type="fig"}.

3.2. Knockdown of NPM1 Gene Resulted in Significant Proteomic Changes in Drug-Resistant Bladder Cancer Cells {#sec3.2}
------------------------------------------------------------------------------------------------------------

The effects of NPM1 gene knockout on cisplatin-resistant bladder cancer cells were analyzed by mass spectrometry. A total of 492 differential proteins were identified by principal component analysis. The identified proteins met the following requirements: fold change \>1.5 (*p* value\<0.05), as shown in [Figure 2(a)](#fig2){ref-type="fig"}.

The changes of cell proteome were quantitatively recorded by tandem mass tag (TMT) technique. A total of 57022 peptides, 54347 unique peptides, and 6686 protein groups were identified in all proteins of the tested cells (FDR \< 0.01). Hierarchical clustering and principal component analysis showed that there were significant protein differences between the gene silencing group and the negative control groups, as shown in [Figure 2(b)](#fig2){ref-type="fig"}. A total of 264 functional proteins were downregulated and 228 functional proteins were upregulated in the gene silencing group compared with those of the negative controls. We further analyzed the biological functions of 492 differential proteins by GO analysis, as shown in [Figure 2(c)](#fig2){ref-type="fig"}. These results confirmed that the proteins affected by NPM1 cover a large number of proteins with biological functions. We specifically analyzed the differential protein of the signal transduction protein in drug-resistant bladder cancer, as shown in [Table 3](#tab3){ref-type="table"}.

3.3. CD40 Is the Most Significantly Downregulated Protein after NPM1 Silencing in Cisplatin-Resistant Bladder Cancer Cells {#sec3.3}
--------------------------------------------------------------------------------------------------------------------------

After NPM1 silencing, the differential expression of proteins was ranked from high to low in cisplatin-resistant bladder cancer cells and found that downregulation of CD40 expression was the most obvious (fold change: −2.66), as shown in [Table 4](#tab4){ref-type="table"}.

Western blot showed that the expression of CD40 in three NPM1 silencing bladder cancer cell lines was downregulated. In the western blot analysis, the level of CD40 protein in the T24/0.8DDP Lv-NPM1 cell line was 0.61-fold as high as that in T24/0.8DDP Lv-NC (*p* \< 0.05). The level of CD40 protein in the BIU-87/0.3DDP Lv-NPM1 cell line was 0.65-fold as high as that in the corresponding negative control BIU-87/0.3DDP Lv-NC (*p* \< 0.05). The level of CD40 protein in the PUMC-91/0.6DDP Lv-NPM1 cell line was 0.56-fold as high as that in the corresponding negative control PUMC-91/0.6DDP Lv-NC (*p* \< 0.05). This results were consistent with those of mass spectrometry, as shown in [Figure 3](#fig3){ref-type="fig"}.

This results were consistent with those of mass spectrometry. This result was confirmed by western blot in three NPM1 silencing bladder cancer cell lines (T24/0.8DDP Lv-NPM1, BIU87/0.3DDP Lv-NPM1, and PUMC-91/0.6DDP Lv-NPM1).

4. Discussion {#sec4}
=============

Because bladder cancer is prone to drug resistance and recurrence, it makes it difficult for a reasonable and targeted treatment strategy. Timely screening or monitoring can help doctors prevent and treat the disease as soon as possible.

In order to improve the sensitivity of early diagnosis and alleviate the pain of patients, the researchers are trying to find some noninvasive biomarkers of bladder cancer for clinical practice. Noninvasive biomarkers of bladder cancer have been found to monitor the prognosis of normal bladder cancer \[[@B15]\], such as cytokeratin 18 protein fragment \[[@B16]\]. But there no sensitive and specific biomarker has been found that can early monitor the progress of drug-resistant bladder cancer.

Nucleophosmin (NPM1) is a protein biomarker that can reflect the therapeutic effect of chemotherapy \[[@B17]\], which not only has the function of monitoring the progression in hematological diseases \[[@B18], [@B19]\], but also has differential expression in some solid tumors such as colon cancer \[[@B20]\] and lung adenocarcinoma \[[@B21]\]. In proteomic analysis of drug-resistant bladder cancer, the expression of NPM1 has been proved to be significantly different \[[@B22]\]. It has also been reported that NPM1 can be used as a valuable prognostic marker of disease \[[@B23], [@B24]\].

In our previous experiments \[[@B10]\], it has been confirmed that the differential expression of NPM1 can reflect the oncological characteristics of cisplatin-resistant bladder cancer. Downregulation of NPM1 can accelerate the invasion and the growth of cisplatin-resistant bladder cancer. In addition, NPM1 can also reflect the development of cisplatin-resistant bladder cancer. However, as the protein is located in the nucleolus, NPM1 can hardly be monitored as early as to be found as extracellular proteins, which limits its value as a biomarker of tumor in the urine.

CD40, a member of the superfamily of tumor necrosis factor receptors involved in cell differentiation \[[@B25]\], has been proved to be an effective tumor marker in many tumors \[[@B26]--[@B28]\], especially in non-B-cell-derived solid tumors, such as nasopharyngeal carcinoma \[[@B29]\], normal bladder cancer \[[@B12]\], cervical cancer \[[@B30]\], and renal cancer \[[@B11]\]. In addition, CD40 has gradually become an effective target for immunotherapy \[[@B31]\].

CD40 can be detected in the exosomes \[[@B32]\]. Some studies have confirmed that CD40 is easy to be monitored early and is related to urinary system diseases such as renal cell carcinoma \[[@B9]\]. However, the value of CD40 in drug-resistant bladder cancer has not yet been evaluated. If we can determine the relationship between CD40 and functional proteins in drug-resistant bladder cancer, we can greatly expand the application of CD40.

To evaluate the value of CD40 as a biomarker in cisplatin-resistant bladder cancer, we established NPM1 silencing stable cell lines by lentivirus infection in three cisplatin-resistant bladder cancer cell lines. According to the research experience, three kinds of drug-resistant bladder cancer can better illustrate the experimental results \[[@B33]--[@B35]\]. The results showed that the knockdown efficiency of the *NPM1* gene was about 70%, which suggests that silencing the *NPM1* gene by lentivirus is effective. The most representative T24 cell line in these three kinds of cell lines was further quantitatively analyzed by mass spectrometry. After NPM1 gene silencing, 492 differential proteins were detected by mass spectrometry, whose variation was more than 1.5 times (*p* \< 0.05). A total of 57022 peptides, 54347 unique peptides, and 6686 protein groups were identified in all proteins of the tested cells (FDR \< 0.01). Hierarchical clustering and principal component analysis showed that 264 functional proteins were downregulated and 228 functional proteins were upregulated in the gene silencing group compared with those of the negative controls. By GO analysis, the proteins affected by NPM1 cover a large number of proteins with biological functions, which may play an important role in the development of tumor in 492 differential proteins. The pathogenesis of oncology often needs to be explained by the changes of the protein in the signal transduction pathway. In MS analysis, the differential expression of NPM1 results in the change of a large number of functional proteins, in which most of them were signal transduction proteins. NF-kappa B signaling pathway can be involved in cell response of cells to external stimuli, such as the effect of cisplatin on drug-resistant bladder cancer. Interestingly, NPM1 has also been proved as an NF-kappaB coactivator for inducting human gene resistance to cell adverse factors \[[@B36]\]. It has been proved that CD40 can regulate the expression of the NF-kappa B signaling pathway through the noncanonical pathway \[[@B37], [@B38]\].

We further found that CD40 was the most significantly downregulated protein after NPM1 silencing, with a difference of 2.6 times change in abundance, whose expression was positively correlated with NPM1 expression.

The results showed that the variation characteristics of CD40 and NPM1 were consistent. Based on our experimental results and other research studies on NPM1 and CD40, we summarized the related pathways of CD40 and NPM1, as shown in [Figure 4](#fig4){ref-type="fig"}. CD40 can be related to the survival, growth, and prognosis of tumors and reflects the changes of the NF-kappa B pathway related to NPM1. In the future, we need further experiments, such as effects of overexpression of CD40 and inhibition of CD40 on the expression of NPM1, to support the claim that NPM1 and CD40 change consistently.

5. Conclusion {#sec5}
=============

In view of the downregulation of CD40 expression in cisplatin-resistant bladder cancer cells after NPM1 silencing, CD40 can be related to the survival, growth, and prognosis of tumors and reflects the changes of the NF-kappa B pathway related to NPM1, which indicates CD40 could be used as a biomarker to monitor the progression of cisplatin-resistant bladder cancer.
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![The stable NPM1 silencing cell lines (T24/0.8DDP Lv-NPM1, BIU-87/0.3DDP Lv-NPM1, and PUMC-91/0.6DDP Lv-NPM1) and the corresponding negative control cell lines (T24/0.8DDP Lv-NC, BIU-87/0.3DDP Lv-NC, and PUMC-91/0.6DDP Lv-NC).](JO2020-3676751.001){#fig1}

![Screening and counting of total differential proteins by mass spectrometry (NPM1 silencing cisplatin-resistant bladder cancer cells and negative control). (a) is the volcanic maps of all proteins present in mass spectrometry. (b) shows the total number of differential screening proteins (fold change \>1.5, *p* value\<0.05). (c) shows the total number of differential proteins with biological function proved by GO analysis (fold change \>1.5, *p* value\<0.05).](JO2020-3676751.002){#fig2}

![CD40 expression in the NPM1 silencing cisplatin-resistant bladder cell line and the negative control group.](JO2020-3676751.003){#fig3}

![Analysis of signal pathways related to CD40 and NPM1.](JO2020-3676751.004){#fig4}

###### 

Variation of separation gradient of mass spectrometry.

  Time (min)   The ratio (%) of gradient solution *B*
  ------------ ----------------------------------------
  0            5
  5            8
  35           18
  62           32
  64           95
  68           95
  72           5

###### 

Parameter settings for MaxQuant search.

  Parameters                     Value
  ------------------------------ ---------------------------------------
  Enzyme                         Trypsin
  Static modification            C-carboxyamidomethylation (57.021 Da)
  Dynamic modification           M oxidation (15.995 Da);
  N-terminal TMT 9 plex          
  Species                        *Homo sapiens*
  Precursor ion mass tolerance   +15 ppm
  Fragmentation mass tolerance   +20 MMU
  Max missed cleavages           2

###### 

Downregulated proteins with signal transduction function in GO analysis (fold change \>1.5, *p* \< 0.05).

  Id                 Accession    Gene name     Description
  ------------------ ------------ ------------- ------------------------------------------------------------------------------------------------------
  TNR5_HUMAN         P25942       CD40          Tumor necrosis factor receptor superfamily member 5
  NPM_HUMAN          P06748       NPM1          Nucleophosmin
  TNR6_HUMAN         P25445       FAS           Tumor necrosis factor receptor superfamily member 6
  IF16_HUMAN         Q16666       IFI16         Gamma-interferon-inducible protein 16
  BID_HUMAN          P55957       BID           BH3-interacting domain death agonist
  E9PCH4_HUMAN       E9PCH4                     Uncharacterized protein
  DAP1_HUMAN         P51397       DAP           Death-associated protein 1
  CNBP1_HUMAN        Q9NSA3       CTNNBIP1      Beta-catenin-interacting protein 1
  ASPH_HUMAN         Q12797       ASPH          Aspartyl/asparaginyl beta-hydroxylase
  A4_HUMAN           P05067       APP           Amyloid-beta A4 protein
  GNAQ_HUMAN         P50148       GNAQ          Guanine nucleotide-binding protein G(q) subunit alpha
  K2C8_HUMAN         P05787       KRT8          Keratin, type II cytoskeletal 8
  SP110_HUMAN        Q9HB58       SP110         Sp110 nuclear body protein
  SDC4_HUMAN         P31431       SDC4          Syndecan-4
  CO1A2_HUMAN        P08123       COL1A2        Collagen alpha-2(I) chain
  HNRDL_HUMAN        O14979       HNRNPDL       Heterogeneous nuclear ribonucleoprotein D-like
  CAB39_HUMAN        Q9Y376       CAB39         Calcium-binding protein 39
  ERLN2_HUMAN        O94905       ERLIN2        Erlin-2
  CY24 A_HUMAN       P13498       CYBA          Cytochrome b-245 light chain
  SLK_HUMAN          Q9H2G2       SLK           STE20-like serine/threonine-protein kinase
  CGL_HUMAN          P32929       CTH           Cystathionine gamma-lyase
  F5H6H0_HUMAN       F5H6H0       HMGA2         High-mobility group protein HMGI-C
  SKI_HUMAN          P12755       SKI           Ski oncogene
  BI2L1_HUMAN        Q9UHR4       BAIAP2L1      Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1
  RHG19_HUMAN        Q14CB8       ARHGAP19      Rho GTPase-activating protein 19
  PTEN_HUMAN         P60484       PTEN          Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
  CCNA2_HUMAN        P20248       CCNA2         Cyclin-A2
  PARK7_HUMAN        Q99497       PARK7         Protein/nucleic acid deglycase DJ-1
  APOE_HUMAN         P02649       APOE          Apolipoprotein E
  IKKA_HUMAN         O15111       CHUK          Inhibitor of nuclear factor kappa-B kinase subunit alpha
  RO52_HUMAN         P19474       TRIM21        E3 ubiquitin-protein ligase TRIM21
  RWDD1_HUMAN        Q9H446       RWDD1         RWD domain-containing protein 1
  AATC_HUMAN         P17174       GOT1          Aspartate aminotransferase, cytoplasmic
  ZFY27_HUMAN        Q5T4F4       ZFYVE27       Protrudin
  SPTN2_HUMAN        O15020       SPTBN2        Spectrin beta chain, nonerythrocytic 2
  SRPRB_HUMAN        Q9Y5M8       SRPRB         Signal recognition particle receptor subunit beta
  KBTB7_HUMAN        Q8WVZ9       KBTBD7        Kelch repeat and BTB domain-containing protein 7
  DDX54_HUMAN        Q8TDD1       DDX54         ATP-dependent RNA helicase DDX54
  A0A0B4J1V8_HUMAN   A0A0B4J1V8   PPAN-P2RY11   HCG2039996
  STAT2_HUMAN        P52630       STAT2         Signal transducer and activator of transcription 2
  ITPR3_HUMAN        Q14573       ITPR3         Inositol 1,4,5-trisphosphate receptor type 3
  TM109_HUMAN        Q9BVC6       TMEM109       Transmembrane protein 109
  K7EM85_HUMAN       K7EM85       ARHGAP45      Rho GTPase-activating protein 45
  IDE_HUMAN          P14735       IDE           Insulin-degrading enzyme
  RADI_HUMAN         P35241       RDX           Radixin
  SEM7A_HUMAN        O75326       SEMA7A        Semaphorin-7A
  RHG24_HUMAN        Q8N264       ARHGAP24      Rho GTPase-activating protein 24
  ERLN1_HUMAN        O75477       ERLIN1        Erlin-1

###### 

The differential expression of proteins in cisplatin-resistant bladder cancer cells after NPM1 silencing.

  Differential protein                                         Ratio
  ------------------------------------------------------------ ----------
  Tumor necrosis factor receptor superfamily member 5 (CD40)   −2.66129
  Nucleophosmin (NPM1)                                         −1.98803

[^1]: Academic Editor: Yongzhong Hou
